Amgen olpasiran may fill critical treatment gap in lowering Lp(a): GlobalData
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
ABB India has secured an order from Reliance Life Sciences to deploy automation and control solutions for their new biosimilars and plasma proteins manufacturing facilities in Nashik, Maharashtra
Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
The product basket increased to 1800 medicines and 285 Surgical Equipment
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Subscribe To Our Newsletter & Stay Updated